Diagnos increases financing to $3.65-million

Executive Summary

• Diagnos Inc. has upsized its previously announced brokered private placement to raise up to $3.65 million due to strong investor demand.
• The offering consists of units priced at $0.30 per unit, with each unit comprising one common share and one common share purchase warrant.
• The transaction is led by Centurion One Capital Corp., with gross proceeds allocated to regulatory affairs, product development, and general corporate purposes.

Key Details

• Total Gross Proceeds: Up to approximately $3.65 million.
• Unit Price: $0.30 per unit.
• Units Issued: Up to 12,166,667 units.
• Warrant Terms: Each unit includes one common share purchase warrant; each full warrant allows the purchase of one share at $0.40 per share for a period of 18 months following the closing date.
• Over-Allotment Option: The agent has an option to increase the offering by up to 1.75 million units for an additional $525,000 in gross proceeds, exercisable prior to two business days before the last closing.
• Lead Agent/Sole Bookrunner: Centurion One Capital Corp.
• Use of Proceeds: Regulatory affairs, product development, business development, and general corporate purposes.
• Closing Date: Expected on or around December 3, 2025, subject to conditions including TSX Venture Exchange approval.
• Hold Period: Four months and one day from the closing date under applicable Canadian securities laws.
• Insider Participation: Insiders and the lead agent may acquire up to 50% of the offering; this is expected to be exempt from formal valuation and minority shareholder approval requirements under MI 61-101.
• Jurisdictions: Offered in British Columbia, Alberta, Ontario, Quebec, the United States (under exemption from Securities Act of 1933), and other mutually agreed jurisdictions.

Notable Quotes

• None provided in the text.